Radiation-Induced Vaccination to Breast Cancer
Abstract
This study combines the TGFbeta neutralizing antibody, Fresolimumab, with Radiation Therapy (RT) to treat advanced metastatic breast cancer. Fresolimumab was given 5 times as either 1 mg/kg or 10 mg/kg 3-weekly schedules. RT is limited to IGRT (3 x 7.5 Gy) to 1-2 lesions with other lesions being designated as sentinels to determine abscopal responses that are hypothesized to be due to RT-induced vaccination. RT was started 10 days after the first and 3rd dose of Fresolimumab The primary objectives are to assess safety, feasibility, and abscopal tumor regression and to monitor immune responses in these patients. The abscopal responses are assessed by imaging. The UCLA component is 3 fold: 1) to enroll 15 patients into the clinical trial, 2) to assess immune responses using blood samples before, during and after treatment by multi-channel flow cytometry for immune monitoring, 3) to examine the effects of targeting TGF-beta on the activities and numbers of breast cancer stem cells with and without irradiation.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2013
- Accession Number
- ADA597852
Entities
People
- William H. Mcbride
Organizations
- University of California, Los Angeles